Study guide

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins

Key Takeaways Explain This Topic AI

Fatty acid beta-oxidation occurs in the mitochondrial matrix; long-chain fatty acids require the carnitine shuttle, wherein carnitine palmitoyltransferase-I (CPT-I) catalyzes the rate-limiting step and is allosterically inhibited by malonyl-CoA.

Systemic primary carnitine deficiency and medium-chain acyl-CoA dehydrogenase (MCAD) deficiency both present with fasting hypoketotic hypoglycemia and lethargy; MCAD deficiency is distinguished by dicarboxylic aciduria (C6-C10) and elevated octanoylcarnitine.

Beta-oxidation of odd-chain fatty acids yields propionyl-CoA, which is converted to methylmalonyl-CoA via biotin-dependent propionyl-CoA carboxylase, and subsequently to succinyl-CoA via vitamin B12-dependent methylmalonyl-CoA mutase; odd-chain fatty acids, together with the glycerol backbone of triglycerides, are thus the only lipid sources of net glucose.

Ketogenesis occurs exclusively in hepatocyte mitochondria via rate-limiting HMG-CoA synthase; hepatocytes cannot utilize ketone bodies because they lack thiophorase (succinyl-CoA:3-ketoacid CoA transferase), and erythrocytes cannot use ketones because they lack mitochondria.

Familial dyslipidemias exhibit distinct podiatric and vascular phenotypes: Type I (LPL/ApoC-II deficiency) causes massive hypertriglyceridemia, eruptive xanthomas, and pancreatitis without premature atherosclerosis; Type IIa (Familial Hypercholesterolemia, LDLR/ApoB-100 defect) causes severe LDL elevations, premature atherosclerosis, and characteristic Achilles tendon xanthomas; Type III (ApoE2/E2) causes palmar xanthomas (xanthoma striatum palmare).

Last updated: October 2026

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins

Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Introduction to Lipid Metabolism

Lipids serve three fundamental biological mandates in human physiology: dense metabolic energy storage (triacylglycerols yielding 9 kcal/g compared to 4 kcal/g for carbohydrates and proteins), structural membrane compartmentalization (phospholipids, sphingolipids, and unesterified cholesterol), and endocrine signaling (steroid hormones, eicosanoids, and secondary messengers). On the APMLE Part I examination, lipid biochemistry is tested with heavy clinical emphasis on the enzymatic checkpoints of fatty acid oxidation, inborn errors of mitochondrial transport, the metabolic partition between ketogenesis and ketolysis, cholesterol homeostasis, and the genetic dyslipidemias that precipitate premature peripheral arterial disease (PAD) and characteristic cutaneous and tendinous xanthomas in the lower extremity. Global Lipid Flux in Human Metabolism

  • ADIPOSE TISSUE LIVER (Mitochondria & Cytosol)
  • ┌──────────────┐ ┌───────────────────────────────┐
  • │ Triglycerides│ │ Fatty Acyl-CoA │
  • └──────┬───────┘ └───┬───────────────────────┬───┘
  • │ Lipolysis (HSL) │ Carnitine Shuttle │ Cytosolic HMG-CoA
  • ▼ ▼ (CPT-I) ▼ Reductase
  • Free Fatty Acids ──[Serum Albumin]──> Beta-Oxidation Cholesterol Synthesis
  • │ │
  • ▼ ▼
  • Acetyl-CoA Lipoproteins
  • │ │ (VLDL, LDL, HDL)
  • Ketogenesis │ ▼ TCA Cycle
  • ▼ (CO2 + H2O + ATP)
  • Ketone Bodies
  • (Acetoacetate, B-OHB)
  • │
  • ▼
  • EXTRAHEPATIC TISSUES
  • (Brain, Heart, Skeletal Muscle)
  • Thiophorase-Dependent Ketolysis
  • Fatty Acid Activation & The Carnitine Shuttle

Before long-chain fatty acids (LCFAs, typically 14 to 20 carbons, such as palmitate [16:0]) can undergo mitochondrial beta-oxidation, they must be activated in the cytoplasm and transported across the impermeable inner mitochondrial membrane (IMM). The Carnitine Shuttle Machinery

  • CYTOSOL OUTER MITOCHONDRIAL INNER MITOCHONDRIAL MITOCHONDRIAL
  • MEMBRANE MEMBRANE MATRIX
  • Fatty Acid + CoA + 2 ATP
  • │ (Acyl-CoA Synthetase)
  • ▼
  • Fatty Acyl-CoA ──────────────> [ CPT-I ]
  • │ (Inhibited by Malonyl-CoA)
  • Carnitine ────────────────────────┼────────┐
  • │ ▼
  • └──> Fatty Acylcarnitine ───┐
  • │
  • ┌───────────────────────────┘
  • ▼
  • [ Translocase ] ───> Fatty Acylcarnitine
  • (CACT Antiporter) │
  • ▲ ▼
  • │ [ CPT-II ] ──> Fatty Acyl-CoA
  • └────── Carnitine ◄─┘ │
  • ▼
  • Beta-Oxidation
  • 1. Fatty Acid Activation (Outer Mitochondrial Membrane / ER)

Cytoplasmic free fatty acids are converted to high-energy fatty acyl-CoA thioesters by fatty acyl-CoA synthetase (thiokinase) located on the outer mitochondrial membrane and endoplasmic reticulum: Fatty Acid + CoA-SH + ATP ⟶ Fatty Acyl-CoA + AMP + PP i \text{Fatty Acid} + \text{CoA-SH} + \text{ATP} \longrightarrow \text{Fatty Acyl-CoA} + \text{AMP} + \text{PP}_i Fatty Acid + CoA-SH + ATP ⟶ Fatty Acyl-CoA + AMP + PP i ​

The inorganic pyrophosphate ( P P i PP_i P P i ​ ) generated is immediately hydrolyzed to 2 P i 2 P_i 2 P i ​ by ubiquitous pyrophosphatase, driving the reaction irreversibly forward. Thus, activating a single fatty acid molecule consumes two high-energy phosphate equivalents (the energetic equivalent of 2 ATP → 2 ADP 2 \text{ ATP} \rightarrow 2 \text{ ADP} 2 ATP → 2 ADP ). Short-chain (2-4 carbons) and medium-chain (6-12 carbons) fatty acids can cross the inner mitochondrial membrane by simple diffusion without activation or carrier systems.

2. The Carnitine Shuttle (Inner Mitochondrial Membrane Entry)

Long-chain fatty acyl-CoA cannot directly cross the inner mitochondrial membrane. The carnitine shuttle translocates acyl moieties into the matrix via three sequential transport steps:

Carnitine Palmitoyltransferase-I (CPT-I / CAT-I): Located on the outer mitochondrial membrane. Trans-esterifies the fatty acyl group from coenzyme A to the hydroxyl group of carnitine, generating fatty acylcarnitine and releasing free cytosolic CoA-SH.

Rate-Limiting Step: CPT-I represents the obligate, rate-limiting control point for all mitochondrial fatty acid oxidation.

Allosteric Regulation: Potently and allosterically inhibited by Malonyl-CoA , the first committed intermediate of de novo fatty acid synthesis produced by acetyl-CoA carboxylase (ACC). When carbohydrate energy is abundant and insulin is elevated, active fatty acid synthesis elevates cytosolic malonyl-CoA, shutting down CPT-I. This prevents a futile cycle wherein newly synthesized fatty acids would be immediately shunted into beta-oxidation.

Carnitine-Acylcarnitine Translocase (CACT): An inner mitochondrial membrane antiporter that shuttles fatty acylcarnitine into the matrix while simultaneously transporting free carnitine back into the intermembrane space.

Carnitine Palmitoyltransferase-II (CPT-II / CAT-II): Located on the matrix-facing inner mitochondrial membrane. Reverses the trans-esterification, transferring the fatty acyl group from carnitine back to a mitochondrial matrix CoA-SH, regenerating mitochondrial fatty acyl-CoA and free carnitine.

  • 3. Inborn Errors of Carnitine Transport & Oxidation
  • Systemic Primary Carnitine Deficiency

Etiology: Autosomal recessive defect in the high-affinity organic cation transporter 2 ( OCTN2 / SLC22A5 ), preventing cellular carnitine uptake in renal tubules, skeletal muscle, and myocardium. Carnitine is lost in urine, depleting systemic stores.

Pathophysiology: Inability to transport long-chain fatty acids into mitochondria arrests beta-oxidation. Impaired beta-oxidation starves hepatocytes of acetyl-CoA, shutting down both gluconeogenesis (pyruvate carboxylase requires acetyl-CoA) and ketogenesis.

Clinical Manifestations: Fasting hypoketotic hypoglycemia , generalized muscle weakness, hypotonia, dilated or hypertrophic cardiomyopathy, hepatic steatosis, and lethargy. Markedly reduced plasma carnitine levels.

Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

Etiology: Autosomal recessive deficiency in the mitochondrial enzyme medium-chain acyl-CoA dehydrogenase, which catalyzes the first step of beta-oxidation for fatty acids 6 to 12 carbons in length.

Pathophysiology: Long-chain fatty acids enter the matrix and undergo beta-oxidation until they reach medium-chain length (C6-C12), where degradation halts. Medium-chain acyl compounds accumulate and spill into alternative microsomal omega-oxidation , producing dicarboxylic acids (e.g., adipic and suberic acids).

Clinical Presentation: Typically manifests in infants (6 to 24 months of age) during prolonged fasting or intercurrent infections (viral gastroenteritis, URI). Presents with severe hypoketotic hypoglycemia , hyperammonemia, metabolic acidosis, vomiting, lethargy, seizures, hepatomegaly, and coma. MCAD deficiency is a major recognized cause of sudden unexpected infant death.

Diagnostic Hallmarks: Elevated plasma octanoylcarnitine (C8-acylcarnitine) on tandem mass spectrometry newborn screening; dicarboxylic aciduria (C6 to C10 dicarboxylic acids in urine); absent or trace urine ketones despite profound hypoglycemia.

Management: Avoid prolonged fasting (>4 hours in neonates), maintain a high-carbohydrate, low-fat diet, and administer IV dextrose emergently during acute catabolic illness.

Important

Board Exam Differential: Hypoketotic Hypoglycemia: Hypoglycemia without serum/urinary ketones is the defining hallmark of an inborn error of fatty acid beta-oxidation. Always differentiate:

Systemic Carnitine Deficiency: Defective carnitine transporter ( OCTN2 ); very low serum carnitine; elevated free fatty acids; cardiomyopathy; muscle weakness.

MCAD Deficiency: Normal carnitine transport; C8-acylcarnitine elevated; pathognomonic urinary dicarboxylic acids (C6-C10) ; normal heart; fasting lethargy and encephalopathy.

Mitochondrial Beta-Oxidation & Odd-Chain Fatty Acid Degradation

Once inside the mitochondrial matrix, fatty acyl-CoA enters the repetitive four-step cyclic pathway of beta-oxidation. Each turn of the spiral shortens the acyl chain by two carbons, releasing one molecule of Acetyl-CoA , one molecule of F A D H 2 FADH_2 F A D H 2 ​ , and one molecule of N A D H NADH N A DH . The Four Steps of the Beta-Oxidation Spiral

  • Fatty Acyl-CoA (n carbons)
  • │
  • │ Step 1: Oxidation (Acyl-CoA Dehydrogenase)
  • ├──────────────────────────> FAD ──> FADH2 (ETC Complex II)
  • ▼
  • trans-delta2-Enoyl-CoA
  • │
  • │ Step 2: Hydration (Enoyl-CoA Hydratase)
  • ├──────────────────────────> H2O added across double bond
  • ▼
  • L-3-Hydroxyacyl-CoA
  • │
  • │ Step 3: Oxidation (3-Hydroxyacyl-CoA Dehydrogenase)
  • ├──────────────────────────> NAD+ ──> NADH + H+ (ETC Complex I)
  • ▼
  • 3-Ketoacyl-CoA
  • │
  • │ Step 4: Thiolysis (Beta-Ketothiolase)
  • ├──────────────────────────> CoA-SH
  • ▼
  • Fatty Acyl-CoA (n-2 carbons) + Acetyl-CoA (enters TCA or Ketogenesis)
  • Energetics of Even-Chain Fatty Acid Oxidation

For a saturated 16-carbon fatty acid (Palmitate, C 16 H 32 O 2 C_{16}H_{32}O_2 C 16 ​ H 32 ​ O 2 ​ ):

Number of Cycles: n 2 − 1 = 16 2 − 1 = 7 cycles \frac{n}{2} - 1 = \frac{16}{2} - 1 = 7\text{ cycles} 2 n ​ − 1 = 2 16 ​ − 1 = 7 cycles .

Products Generated: 8 Acetyl-CoA + 7 F A D H 2 + 7 N A D H 8\text{ Acetyl-CoA} + 7\text{ }FADH_2 + 7\text{ }NADH 8 Acetyl-CoA + 7 F A D H 2 ​ + 7 N A DH .

ATP Yield Calculation:

8 Acetyl-CoA × 10 ATP (TCA cycle) = 80 ATP 8\text{ Acetyl-CoA} \times 10\text{ ATP (TCA cycle)} = 80\text{ ATP} 8 Acetyl-CoA × 10 ATP (TCA cycle) = 80 ATP

7 F A D H 2 × 1.5 ATP (ETC) = 10.5 ATP 7\text{ }FADH_2 \times 1.5\text{ ATP (ETC)} = 10.5\text{ ATP} 7 F A D H 2 ​ × 1.5 ATP (ETC) = 10.5 ATP

7 N A D H × 2.5 ATP (ETC) = 17.5 ATP 7\text{ }NADH \times 2.5\text{ ATP (ETC)} = 17.5\text{ ATP} 7 N A DH × 2.5 ATP (ETC) = 17.5 ATP

Gross Total = 108 ATP = 108\text{ ATP} = 108 ATP

Net Yield = 108 − 2 (Activation) = 106 ATP = 108 - 2\text{ (Activation)} = \mathbf{106\text{ ATP}} = 108 − 2 (Activation) = 106 ATP .

Palmitate provides more than three times the ATP yield of one molecule of glucose (net 30-32 ATP), illustrating why fatty acids represent the primary energetic substrate for resting skeletal muscle and the myocardium.

Odd-Chain Fatty Acid Oxidation & Glucogenic Lipids

Natural plant lipids and marine oils contain odd-numbered carbon chains (e.g., C15, C17). Odd-chain fatty acids undergo standard beta-oxidation until the final thiolytic cleavage yields one molecule of Acetyl-CoA (2C) and one molecule of Propionyl-CoA (3C) . Propionyl-CoA Metabolism Pathway

  • Propionyl-CoA (3C)
  • │
  • │ Propionyl-CoA Carboxylase (Requires BIOTIN / B7, ATP, CO2)
  • ▼
  • D-Methylmalonyl-CoA (4C)
  • │
  • │ Methylmalonyl-CoA Epimerase
  • ▼
  • L-Methylmalonyl-CoA (4C)
  • │
  • │ Methylmalonyl-CoA Mutase (Requires VITAMIN B12 / Cobalamin)
  • ▼
  • Succinyl-CoA (4C) ───> Enters TCA Cycle ───> Malate ───> Gluconeogenesis

Propionyl-CoA Carboxylase: Adds a carboxyl group to propionyl-CoA, forming D-methylmalonyl-CoA. Requires Biotin (Vitamin B 7 B_7 B 7 ​ ) , ATP, and C O 2 CO_2 C O 2 ​ . (Deficiency of this enzyme causes Propionic Acidemia ).

Methylmalonyl-CoA Epimerase: Converts D-methylmalonyl-CoA to the L-enantiomer.

Methylmalonyl-CoA Mutase: Catalyzes a carbon skeleton rearrangement to produce Succinyl-CoA . Requires 5'-deoxyadenosylcobalamin (Vitamin B 12 B_{12} B 12 ​ ) as an obligate cofactor.

Clinical Correlation: In Vitamin B 12 B_{12} B 12 ​ deficiency, methylmalonyl-CoA mutase cannot function, resulting in the massive accumulation of Methylmalonic Acid (MMA) in blood and urine, accompanied by elevated homocysteine. In contrast, pure folate deficiency exhibits elevated homocysteine but normal MMA .

Glucogenic Status: Succinyl-CoA is a four-carbon TCA cycle intermediate that converts to malate, exits the mitochondria, and enters cytosolic gluconeogenesis. Therefore, odd-chain fatty acids are the ONLY fatty acids capable of serving as gluconeogenic precursors in humans .

Ketogenesis & Extrahepatic Ketolysis

When fatty acid beta-oxidation in hepatocytes exceeds the oxidative capacity of the citric acid cycle—such as during prolonged fasting, starvation, exhaustive endurance exercise, or uncontrolled diabetic ketoacidosis (DKA)—acetyl-CoA is diverted into the synthesis of water-soluble ketone bodies . The Hepatic Ketogenesis Pathway

  • 2 Acetyl-CoA
  • │
  • │ Thiolase
  • ▼
  • Acetoacetyl-CoA
  • │
  • │ + Acetyl-CoA
  • │ Mitochondrial HMG-CoA Synthase (RATE-LIMITING)
  • ▼
  • HMG-CoA
  • │
  • │ HMG-CoA Lyase
  • ▼
  • Acetoacetate
  • ┌────┴────────────────────────┐
  • Spontaneous │ │ Beta-Hydroxybutyrate
  • Decarboxylation │ │ Dehydrogenase (NADH -> NAD+)
  • ▼ ▼
  • Acetone Beta-Hydroxybutyrate
  • (Fruity Breath, Exhaled) (Predominant in DKA, Blood)
  • 1. Hepatic Ketogenesis Cascade

Ketogenesis occurs exclusively within the mitochondrial matrix of hepatocytes :

Condensation: Two molecules of acetyl-CoA condense via mitochondrial thiolase to form acetoacetyl-CoA.

Rate-Limiting Step: A third acetyl-CoA is added by mitochondrial HMG-CoA synthase to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). (Note: HMG-CoA synthase has two distinct isozymes: a mitochondrial isozyme dedicated to ketogenesis, and a cytosolic isozyme dedicated to cholesterol synthesis).

Cleavage: HMG-CoA lyase cleaves HMG-CoA into free acetoacetate and releases acetyl-CoA.

Conversion to Peripheral Fuel:

β \beta β -Hydroxybutyrate ( β \beta β -OHB): Acetoacetate is reversibly reduced to β \beta β -hydroxybutyrate by β \beta β -hydroxybutyrate dehydrogenase , coupled to the oxidation of N A D H NADH N A DH to N A D + NAD^+ N A D + . In conditions with a high mitochondrial N A D H / N A D + NADH/NAD^+ N A DH / N A D + ratio (such as active DKA or ethanol intoxication), equilibrium shifts overwhelmingly toward β \beta β -hydroxybutyrate. Consequently, β \beta β -hydroxybutyrate is the predominant circulating ketone body in DKA (often exceeding acetoacetate by a 5:1 to 10:1 ratio).

Acetone: Acetoacetate slowly and non-enzymatically undergoes spontaneous decarboxylation to form volatile acetone , which is excreted via the pulmonary capillaries into expired air, producing the classic fruity, sweet breath odor in patients with diabetic ketoacidosis.

2. Extrahepatic Ketolysis (Peripheral Utilization)

Ketone bodies are released from hepatocytes into the systemic circulation to serve as vital water-soluble energy fuels for extrahepatic tissues (skeletal muscle, cardiac muscle, renal cortex, and during prolonged starvation, the brain, which adapts to derive up to 60-70% of its total energy from β \beta β -hydroxybutyrate):

In target extrahepatic mitochondria, β \beta β -hydroxybutyrate is oxidized back to acetoacetate by β \beta β -hydroxybutyrate dehydrogenase ( N A D + → N A D H NAD^+ \rightarrow NADH N A D + → N A DH ).

Acetoacetate is then activated to acetoacetyl-CoA by the enzyme Thiophorase (also known as Succinyl-CoA:3-ketoacid CoA transferase / SCOT ), which transfers a coenzyme A moiety from succinyl-CoA (generating succinate): Acetoacetate + Succinyl-CoA ⟶ Thiophorase Acetoacetyl-CoA + Succinate \text{Acetoacetate} + \text{Succinyl-CoA} \stackrel{\text{Thiophorase}}{\longrightarrow} \text{Acetoacetyl-CoA} + \text{Succinate} Acetoacetate + Succinyl-CoA ⟶ Thiophorase ​ Acetoacetyl-CoA + Succinate

Acetoacetyl-CoA is subsequently cleaved by thiolase into two molecules of acetyl-CoA, which enter the citric acid cycle for ATP generation.

Important

Two Board-Tested Exceptions to Ketone Body Utilization:

The Liver: Hepatocytes lack Thiophorase (SCOT) . Consequently, while the liver is the sole major factory producing ketone bodies for the rest of the body, the liver cannot consume ketone bodies for its own metabolic needs, avoiding an unproductive futile cycle.

Mature Erythrocytes: Red blood cells lack mitochondria entirely and thus possess no beta-oxidation, TCA cycle, or ketolysis enzymes; erythrocytes remain strictly dependent on anaerobic glycolysis and glucose.

Cholesterol Biosynthesis & Statin Pharmacology

Cholesterol is an indispensable lipid component of eukaryotic cell membranes, modulating membrane fluidity, and acts as the universal biochemical precursor for bile acids, steroid hormones (cortisol, aldosterone, testosterone, estradiol), and Vitamin D. Cholesterol Biosynthesis Cascade

  • 3 Acetyl-CoA ───> Acetoacetyl-CoA ───> Cytosolic HMG-CoA
  • │
  • │ HMG-CoA Reductase (ER Membrane)
  • │ - Rate-Limiting Step
  • │ - Consumes 2 NADPH
  • │ - COMPETITIVELY INHIBITED BY STATINS
  • ▼
  • Mevalonate
  • │
  • ▼ (Multiple Phosphorylations & Decarboxylation)
  • Isopentenyl Pyrophosphate (IPP, 5C)
  • │
  • ▼
  • Geranyl Pyrophosphate (10C)
  • │
  • ▼
  • Farnesyl Pyrophosphate (FPP, 15C)
  • │
  • ▼ Squalene Synthase
  • Squalene (30C)
  • │
  • ▼ Squalene Epoxidase & Cyclase
  • Lanosterol (30C)
  • │
  • ▼ (19-Step Modification)
  • CHOLESTEROL (27C)
  • 1. The Rate-Limiting Step: HMG-CoA Reductase

Biosynthesis occurs in the cytoplasm and endoplasmic reticulum (ER) of nucleated cells, predominantly in hepatocytes and enterocytes.

Two molecules of acetyl-CoA condense to form acetoacetyl-CoA, which condenses with a third acetyl-CoA via cytosolic HMG-CoA synthase to generate cytosolic HMG-CoA.

HMG-CoA Reductase: An integral transmembrane glycoprotein of the endoplasmic reticulum that reduces HMG-CoA to Mevalonate , consuming two molecules of NADPH .

This is the committed, irreversible, and rate-limiting step of de novo cholesterol biosynthesis.

2. Multi-Tiered Regulation of HMG-CoA Reductase

Transcriptional Regulation (SREBP-2 / SCAP):

Sterol Regulatory Element-Binding Protein-2 (SREBP-2) is anchored to the ER membrane complexed with SCAP (SREBP Cleavage-Activating Protein) .

When intracellular sterol concentrations fall, SCAP undergoes a conformational shift and escorts SREBP-2 in COPII vesicles to the Golgi apparatus.

In the Golgi, Site-1 Protease (S1P) and Site-2 Protease (S2P) cleave SREBP-2, liberating its soluble basic helix-loop-helix transcription factor domain.

The liberated domain migrates to the nucleus and binds Sterol Regulatory Elements (SRE) in the promoter regions of target genes, upregulating transcription of both HMG-CoA reductase and the LDL Receptor (LDLR) , stimulating both de novo synthesis and clearance of circulating LDL.

Post-Translational Phosphorylation (AMPK):

Inactivation: AMP-activated protein kinase (AMPK) phosphorylates HMG-CoA reductase, rendering it catalytically inactive. High AMP (low cellular energy) and glucagon stimulate phosphorylation, shutting down cholesterol synthesis to conserve energy.

Activation: Insulin activates protein phosphatase 2A, which dephosphorylates and activates HMG-CoA reductase, stimulating cholesterol synthesis in the well-fed state.

Proteasomal Degradation: Rising intracellular concentrations of cholesterol and oxysterols trigger ubiquitination of HMG-CoA reductase, directing it to the 26S proteasome for degradation.

3. Statin Therapeutics (HMG-CoA Reductase Inhibitors)

Mechanism: Statins (Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin) possess a structural component that closely mimics the 3-hydroxyglutaryl moiety of HMG-CoA. They act as reversible competitive inhibitors of HMG-CoA reductase, binding to its active catalytic site and blocking mevalonate synthesis.

Downstream Cellular Consequence: Decreased intracellular hepatic cholesterol levels relieve SCAP inhibition, triggering SREBP-2 cleavage and nuclear translocation. SREBP-2 dramatically upregulates LDL receptor transcription on the hepatocyte surface. The expanded pool of cell-surface LDL receptors clears circulating atherogenic LDL particles from the bloodstream via receptor-mediated endocytosis, lowering serum LDL-C by 30% to 60%.

Adverse Effects: Statin-associated myopathy/myositis (elevated serum creatine kinase [CK]), myalgias in large muscle groups of the lower extremity (calves, thighs), asymptomatic elevations in hepatic transaminases, and rare rhabdomyolysis (potentiated by concurrent fibrate therapy, particularly gemfibrozil, which inhibits statin glucuronidation).

Lipoprotein Structure, Apolipoproteins & Dynamics

Lipids are completely insoluble in aqueous plasma and must be packaged into spherical, micelle-like macromolecular complexes termed lipoproteins for vascular transport. Each particle possesses a nonpolar hydrophobic lipid core surrounded by an amphipathic monolayer of phospholipids, unesterified cholesterol, and apolipoproteins. Spherical Lipoprotein Architecture

  • Phospholipid Monolayer
  • (Hydrophilic Choline Heads Outward)
  • │
  • ○ ○ ○ ○ ○ ○ ○
  • ○ ○ ── Apolipoprotein (e.g., ApoB-100)
  • ○ HYDROPHOBIC CORE ○
  • ○ - Triglycerides ○ ── Unesterified Cholesterol
  • ○ - Cholesterol Esters○
  • ○ ○
  • ○ ○ ── Apolipoprotein (e.g., ApoE)
  • ○ ○ ○ ○ ○ ○ ○
  • Apolipoprotein Classification & Specific Roles

Apolipoprotein Primary Lipoprotein Association Key Metabolic Role & Clinical Significance

ApoA-I HDL (structural) Activates LCAT (Lecithin-Cholesterol Acyltransferase) ; mediates reverse cholesterol transport; structural backbone of HDL

ApoB-48 Chylomicrons , Chylomicron Remnants Mediates intestinal secretion of dietary lipids into lacteals; derived from APOB mRNA by cytidine deaminase RNA editing ( C → U C \rightarrow U C → U , creating stop codon at 48% length)

ApoB-100 VLDL, IDL, LDL (structural) Full-length structural apolipoprotein synthesized by liver; serves as the obligate ligand for the LDL Receptor (LDLR) mediating endocytosis

ApoC-II Chylomicrons, VLDL, HDL Essential cofactor that activates Lipoprotein Lipase (LPL) on capillary endothelial surfaces, hydrolyzing triglycerides into free fatty acids

ApoE Chylomicrons, VLDL, IDL, HDL Mediates remnant uptake by binding hepatic LDLR and LDL Receptor-Related Protein (LRP); defective binding in ApoE2 homozygotes causes Type III Dyslipidemia The Lipoprotein Transport Cascade

  • EXOGENOUS PATHWAY (Dietary Lipids) ENDOGENOUS PATHWAY (Hepatic Lipids)
  • ┌─────────────────────────────┐ ┌─────────────────────────────┐
  • │ Intestinal Enterocytes │ │ Hepatocytes │
  • │ Secretes: CHYLOMICRONS │ │ Secretes: VLDL │
  • │ (ApoB-48, ApoC-II, ApoE) │ │ (ApoB-100, ApoC-II, ApoE) │
  • └──────────────┬──────────────┘ └──────────────┬──────────────┘
  • │ │
  • ▼ ▼
  • Capillary Bed Capillary Bed
  • [ LPL Activated by ApoC-II ] [ LPL Activated by ApoC-II ]
  • │ │
  • FFA to Muscle & Adipose FFA to Muscle & Adipose
  • │ │
  • ▼ ▼
  • Chylomicron Remnant IDL
  • (ApoB-48, ApoE) (ApoB-100, ApoE)
  • │ ┌──────┴──────┐
  • ▼ Hepatic LDLR / LRP ▼ ▼
  • Cleared by Liver (ApoE) Liver Uptake Hepatic Lipase (HL)
  • ▼
  • LDL
  • (ApoB-100)
  • │
  • Peripheral LDLR ◄──┴──► Hepatic LDLR
  • 1. Chylomicrons (Exogenous Dietary Pathway)

Synthesized in intestinal enterocytes from dietary triglycerides, cholesterol, and fat-soluble vitamins.

Packaged with ApoB-48 and secreted into mesenteric lacteals, entering the systemic venous circulation via the thoracic duct (bypassing the hepatic portal system).

In plasma, nascent chylomicrons acquire ApoC-II and ApoE from circulating mature HDL.

In capillary beds of adipose tissue and skeletal muscle, endothelial Lipoprotein Lipase (LPL) (activated by ApoC-II) hydrolyzes core triglycerides into free fatty acids (used for energy or re-esterified for storage) and glycerol.

As triglycerides are depleted, ApoC-II is transferred back to HDL. The resulting chylomicron remnant (rich in cholesterol esters, retaining ApoB-48 and ApoE) binds hepatic LDL receptors and LRP via ApoE , undergoing endocytic clearance by hepatocytes.

2. VLDL & IDL (Endogenous Hepatic Pathway)

Synthesized in hepatocytes to export endogenous triglycerides to peripheral tissues.

Packaged with full-length ApoB-100 ; acquires ApoC-II and ApoE from HDL.

Endothelial LPL hydrolyzes triglycerides in adipose and muscle, reducing particle volume to form Intermediate-Density Lipoprotein (IDL) .

IDL retains ApoB-100 and ApoE. Approximately 50% of IDL is cleared directly by the liver via ApoE binding to LDLR. The remaining IDL undergoes further triglyceride hydrolysis by hepatic lipase (HL) in hepatic sinusoids, losing ApoE to become Low-Density Lipoprotein (LDL) .

3. LDL & Atherogenesis

LDL carries approximately 70% of total circulating plasma cholesterol. Its sole apolipoprotein is ApoB-100 .

Primary role is delivering cholesterol to peripheral tissues (and back to liver) via LDL Receptor-Mediated Endocytosis :

ApoB-100 binds the extracellular domain of the LDLR on clathrin-coated pits.

The complex is internalized via clathrin-coated endosomes; endosomal acidification dissociates LDL from the receptor; the receptor recycles back to the plasma membrane.

The endosome fuses with a lysosome, where acid lipases degrade ApoB-100 to amino acids and hydrolyze cholesterol esters into free unesterified cholesterol.

Free intracellular cholesterol suppresses HMG-CoA reductase, suppresses LDLR transcription (via SREBP-2), and activates ACAT (Acyl-CoA:Cholesterol Acyltransferase) to store excess cholesterol as intracellular droplet esters.

Atherogenesis in Lower Extremity PAD: When plasma LDL is elevated, excess particles penetrate the permeable endothelial barrier of arteries (e.g., femoral, popliteal, tibial arteries). Within the subendothelial intima, trapped LDL undergoes chemical oxidation ( oxLDL ). oxLDL stimulates endothelial cells to express adhesion molecules (VCAM-1, ICAM-1) and monocyte chemoattractants. Recruited monocytes differentiate into macrophages, which engulf oxLDL via unregulated Scavenger Receptors (SR-A / CD36) . Unrestrained lipid ingestion transforms macrophages into lipid-laden foam cells , forming the pathognomonic fatty streak , followed by smooth muscle migration, collagen deposition, fibrous cap formation, and atherosclerotic plaque progression.

4. HDL & Reverse Cholesterol Transport

HDL is synthesized and secreted as an empty, disk-shaped (nascent) particle by the liver and small intestine, composed primarily of ApoA-I and phospholipids.

Reverse Cholesterol Transport:

Nascent HDL extracts excess unesterified free cholesterol from peripheral cells and arterial macrophages via ABCA1 and ABCG1 lipid transporters.

LCAT (Lecithin-Cholesterol Acyltransferase / PCAT): Activated by ApoA-I on the HDL surface. LCAT transfers a fatty acid from phosphatidylcholine (lecithin) to free cholesterol, generating cholesterol esters and lysolecithin. Hydrophobic cholesterol esters migrate into the particle core, converting flat nascent HDL into mature, spherical H D L 3 HDL_3 HD L 3 ​ and H D L 2 HDL_2 HD L 2 ​ .

CETP (Cholesteryl Ester Transfer Protein): Mediates the reciprocal exchange of cholesterol esters from mature HDL to triglyceride-rich particles (VLDL, IDL, LDL) in exchange for triglycerides. This allows peripheral cholesterol to return to the liver indirectly via LDL-LDLR clearance.

Direct Hepatic Uptake: HDL delivers cholesterol esters directly to hepatocytes via the Scavenger Receptor Class B Type 1 (SR-B1) without particle degradation, allowing HDL to re-enter circulation.

Circulating Reservoir: HDL serves as a circulating storage depot for ApoC-II and ApoE , donating them to nascent chylomicrons and VLDL and retrieving them upon triglyceride depletion.

Familial Dyslipidemias & Lower Extremity Phenotypes

Inherited genetic defects in apolipoproteins, cell-surface receptors, or lipid-processing enzymes produce characteristic patterns of plasma lipid elevation and pathognomonic clinical findings. Classification of Familial Dyslipidemias

  • TYPE I: Hyperchylomicronemia TYPE IIa: Hypercholesterolemia TYPE III: Dysbetalipoproteinemia
  • Defect: LPL or ApoC-II - Defect: LDLR or ApoB-100 - Defect: ApoE2/E2 homozygous
  • Elevated: Chylomicrons (TG >1000) - Elevated: LDL (Cholesterol >300) - Elevated: Chylomicron Remnants & IDL
  • Eruptive Xanthomas - ACHILLES TENDON XANTHOMAS - PALMAR CREASE XANTHOMAS
  • Pancreatitis - Severe Accelerated Atherosclerosis- Premature CAD & PAD
  • NO Premature CAD - Xanthelasma, Arcus Senilis

Type Common Name Inheritance Primary Molecular Defect Elevated Lipoprotein Elevated Serum Lipid Pathognomonic Clinical Manifestations & Lower Extremity Signs

Type I Familial Hyperchylomicronemia Autosomal Recessive Deficiency of Lipoprotein Lipase (LPL) or ApoC-II Chylomicrons Triglycerides (>1000 mg/dL) Eruptive xanthomas (crops of yellow-red papules on buttocks and extensor surfaces of knees/elbows), hepatosplenomegaly, lipemia retinalis, recurrent acute pancreatitis ; NO increased risk of atherosclerosis ; creamy top layer in refrigerated plasma

Type IIa Familial Hypercholesterolemia Autosomal Dominant Mutations in LDL Receptor (LDLR) or ApoB-100 LDL Cholesterol (300-500 mg/dL in heterozygotes; >600-1000 mg/dL in homozygotes) Accelerated atherosclerosis (MI before age 20 in homozygotes, PAD in lower extremity), Tendon xanthomas (pathognomonic firm nodules classically in the Achilles tendon and extensor tendons of fingers), xanthelasma palpebrarum, corneal arcus

Type IIb Familial Combined Hyperlipidemia Autosomal Dominant Decreased LDLR and hepatic overproduction of ApoB-100 LDL + VLDL Cholesterol + Triglycerides Premature CAD, peripheral vascular disease; metabolic syndrome; xanthomas usually absent

Type III Familial Dysbetalipoproteinemia Autosomal Recessive Homozygosity for defective ApoE2 allele ( ApoE2/E2 ); impaired remnant clearance Chylomicron remnants + IDL ( β \beta β -VLDL) Triglycerides + Cholesterol Palmar xanthomas (xanthoma striatum palmare) (orange-yellow discoloration and plaques in palmar creases; pathognomonic), tuboeruptive xanthomas over knees and elbows; accelerated coronary and peripheral atherosclerosis

Type IV Familial Hypertriglyceridemia Autosomal Dominant Hepatic overproduction or impaired catabolism of VLDL VLDL Triglycerides (200-500+ mg/dL) Associated with insulin resistance, obesity, type 2 diabetes mellitus; turbid plasma; elevated risk of acute pancreatitis at TG >1000 mg/dL; xanthomas rare

Note

Podiatric Significance: Achilles Tendon Xanthomas: In podiatric clinical practice, bilateral or unilateral firm, non-tender, nodular fusiform enlargements within the substance of the Achilles tendon are a classic presentation of Familial Hypercholesterolemia (Type IIa) . These lesions represent macrophage foam cell and extracellular cholesterol ester accumulation within tendon fascicles. They are frequently misdiagnosed as chronic Achilles tendinopathy, insertional spurring, or rheumatoid nodules. Any patient presenting with tendon xanthomas requires an immediate fasting lipid panel, cardiovascular evaluation, and aggressive high-intensity statin therapy, as cardiovascular mortality is extraordinarily high if left untreated.